Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models

被引：0
|
作者：
Camilio, Ketil Andre
Sveinbjornsson, Baldur
Maubant, Sylvie
Serin, Guillaume
Mirjolet, Jean-Francois
Bichat, Francis
Rekdal, Oystein
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-328
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
328
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Remission and tumor cell protection in PVG rats by subcutaneous injection of LTX-315 into an aggressive malignant rat mesenchymal tumor with stemness characteristics
    Kvalheim, G.
    Wang, M.
    Zinocker, S.
    Camilio, K.
    Rolstad, B.
    Vaage, J.
    Rekdal, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.
    Nielsen, Morten
    Monberg, Tine
    Albieri, Benedetta
    Sundvold, Vibeke
    Rekdal, Oystein
    Junker, Niels
    Svane, Inge Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma
    Bo Sun
    Jiayun Liu
    Xiaocui Liu
    Jing Li
    Guilin Zhang
    Tao Sun
    Chuansheng Zheng
    Xuefeng Kan
    Cell Death & Disease, 16 (1)
  • [44] A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.
    Spicer, James F.
    Marabelle, Aurelien
    Baurain, Jean-Francois
    Awada, Ahmad
    Kristeleit, Rebecca Sophie
    Jossang, Dag Erik
    Jebsen, Nina
    Loirat, Delphine
    Armstrong, Anne Caroline
    Curigliano, Giuseppe
    Nicolaisen, Berit
    Rekdal, Oystein
    Sveinbjornsson, Baldur
    Gjerstad, Vibeke Sundvold
    Brunsvig, Paal
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma
    Nielsen, Morten
    Monberg, Tine
    Sundvold, Vibeke
    Albieri, Benedetta
    Hovgaard, Dorrit
    Petersen, Michael Mork
    Krarup-Hansen, Anders
    Met, Oezcan
    Camilio, Ketil
    Clancy, Trevor
    Stratford, Richard
    Sveinbjornsson, Baldur
    Rekdal, Oystein
    Junker, Niels
    Svane, Inge Marie
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [46] Intratumoral treatment of one tumor lesion with LTX-315 induces complete tumor regression and long-term specific protective immune responses in a metastatic rodent tumor model
    Rekdal, Oystein
    Nestvold, Janne
    Wang, Meng Y.
    Camilio, Ketil Andre
    Areffard, Ali
    Sveinbjornsson, Baldur
    Kvalheim, Gunnar
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Antitumor activity of lenvatinib against acquired resistance tumor to anti-VEGF therapy in mouse syngeneic tumor models
    Ichikawa, Kenji
    Miyano, Saori Watanabe
    Minoshima, Yukinori
    Matsui, Junji
    Funahashi, Yasuhiro
    CANCER RESEARCH, 2019, 79 (13)
  • [48] In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models
    Jing, Y.
    Zaias, J.
    Duncan, R.
    Russell, S. J.
    Merchan, J. R.
    GENE THERAPY, 2014, 21 (03) : 289 - 297
  • [49] Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models
    Peer, D
    Margalit, R
    NEOPLASIA, 2004, 6 (04): : 343 - 353
  • [50] In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models
    Y Jing
    J Zaias
    R Duncan
    S J Russell
    J R Merchan
    Gene Therapy, 2014, 21 : 289 - 297
12345